# Parkinson's Disease Biomarkers | IXICO

IXICO supports Parkinson's disease clinical trials with advanced neuroimaging and biomarker analysis. Leverage our CNS expertise to advance PD drug development.

# Parkinson's Disease Neuroimaging & Biomarker Services

![PD Left Dark](/assets/element-images/PD-Left-Dark__FitMaxWzk2MCw1NDBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp "PD Left Dark")

IXICO specialises in PD imaging, providing advanced imaging biomarkers to quantify essential PD measurements such as dopamine transporter (DaT) density and brain atrophy for the assessment of drug safety, eligibility and efficacy.

IXICO has supported numerous brain scans collected through a variety of PD research initiatives, promoting innovation and harmonising imaging data for better clinical trial outcomes. The IXI™ platform improves the accuracy and efficiency of volumetric measurements with PD-specific services: extensive imaging support with global site management, centralised radiology reads, PD-specific workflows, and advanced bespoke image analytics.

Work with leading institutions and initiatives, for example, C-Path CPP and tracer manufacturers such as GE, underline IXICO’s expertise, ensures successful outcomes and contributes to IXICO’s position as a dependable partner helping to advance PD research and clinical trials.

### Dopamine transporter (DaT) imaging

Including DaTSPECT, to assess dopamine transporter density in the brain, aiding in patient selection and trial eligibility.

### Tracer-agnostic PET pipeline

Supporting various tracers to measure dopaminergic function and neuroinflammation.

### Quantitative Imaging Endpoints

Amyloid PET Tau PET Structural MRI, Vascular pathology Quantitative Susceptibility Mapping (QSM) Diffusion MRI Arterial Spin Labelling (ASL) MRI Resting State fMRI (rs-fMRI) Free Water imaging

### Neuroimaging Biomarker Analysis

White matter changes Neuromelanin Neuroinflammation

### Neuromelanin (NM) sensitive MRI imaging

Emerging as a relevant measure (pigment found in dopamine neurons) for PD research in PD clinical trials which requires expert understanding of the practical and technical challenges in NM imaging, such as low spatial resolution and long acquisition times.

## Parkinson's Disease Content Portal

### Our PD Factsheet

[    Download ](/assets/downloads/IXICO-Your-Partner-in-Parkinsons-Disease-Imaging-Analysis-and-Operations-Solutions-July-2025-Digital-v3.pdf)

### Blog

The New Research Developments Driving Precision Care in Parkinson’s Disease

[    View Here ](/news-and-resources/blog/the-new-research-developments-driving-precision-care-in-parkinsons-disease/)

### Blog

The Emergence of Neuromelanin-Sensitive Imaging in Parkinson’s Disease Clinical Trials

[    View Here ](/news-and-resources/blog/the-emergence-of-neuromelanin-sensitive-imaging-in-parkinsons-clinical-trials/)

## Other Parkinsonian Disorders

In addition to Parkinson’s Disease, IXICO also specialises in imaging in other Parkinsonian disorders, such as Progressive Supranuclear Palsy (PSP) and Multiple System Atrophy (MSA).

Imaging features can help differentiate PSP and MSA from Parkinson's disease, with distinct visually identifiable features, such as in PSP, where midbrain atrophy results in the Hummingbird appearance on axial T1 MRI images.  Such features are identified by our team of expert neuroradiology readers during control centralised eligibility reads.

Volumetric MRI analysis can be used for quantitative assessment of regional atrophy, as well as functional PET and SPECT imaging, playing a role in the assessment of reduced dopamine transporter binding.

## Recent PD Scientific Publications

**Automated VMAT2 \[18F\] AV-133 PET analysis in Parkinson's disease**

- **Date:** September 8th 2023
- **Synopsis:** This study evaluates a fully automated image analysis pipeline for processing vesicular monoamine transporter type 2 (VMAT2) \[18F\]AV-133 PET images
- **Therapeutic Indication:** Parkinson's Disease (PD)

[**>Study**](/assets/downloads/Automated-VMAT2-18FAV-133-PET-analysis-in-Parkinsons-Disease-MDS-2023.pdf)